DaVita HealthCare (DVA) closed the most recent trading day at $152.69, moving +0.77% from the previous trading session.

The latest trading day saw DaVita HealthCare (DVA) settling at $151.53, representing a -0.84% change from its previous close.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $155.06, denoting a +1.33% change from the preceding trading day.

Warren Buffett is recognized for his legendary ability to uncover high-quality and undervalued companies to invest in. Under his leadership, Berkshire Hathaway (BRK.B 0.86%) (BRK.A 1.37%) has crushed ...

Strength in kidney care services and expansion into international markets raise optimism for DVA stock.

Warren Buffett, the longtime head of Berkshire Hathaway (BRK.A 0.99%) (BRK.B 0.95%), has delivered an impressive nearly 20% annualized return for shareholders since 1965, doubling the S&P 500's benchm...

Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significan...

The company's profitability is going in the wrong direction for many investors.

This week marks a fire hose of earnings from several top Warren Buffett stock holdings. "Extraordinary business" Apple is on deck Thursday.

DVA's robust Dialysis patient service revenues drives its third-quarter performance.

DaVita Inc. (NYSE:DVA ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Offi...

DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, missing the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.85 per share a year ago.

DaVita reported third-quarter profit that missed Wall Street estimates on Tuesday, hurt by high patient care costs.

If you had to choose the best time to invest in the S&P 500 — it's the six months starting in November.

Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.

DaVita HealthCare (DVA) concluded the recent trading session at $163.16, signifying a +1% move from its prior day's close.

In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.

DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.